Selkirk Pharma vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Contract Development & Manufacturing Organization (CDMO) — Sterile Injectables
Selkirk Pharma is a US-based CDMO specializing in aseptic fill/finish for sterile injectable drug products; raised $82M+ total; operates a 115,000 sq ft GMP facility in Spokane, WA; blueprinted a $90M expansion factory;
About
Selkirk Pharma is a contract development and manufacturing organization (CDMO) founded in 2018 by fill/finish industry veterans and headquartered in Spokane, Washington. The company was purpose-built to address the domestic shortage of aseptic fill/finish manufacturing capacity for sterile injectable drug products — a segment critical to biologics, small molecules, and parenteral medicines. Its 115,000-square-foot GMP facility at the Pacific Northwest Technology Park operates with advanced isolator technology from SKAN, Bausch and Strobel VarioSys dose-filling systems, and single-use systems designed to meet both US FDA and EU Annex 1 compliance standards.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.